Hypertrophic Cardiomyopathy Therapeutics Market to Reach USD 1.2 Billion by 2020
Hypertrophic Cardiomyopathy Therapeutics Market – Global HCM Drug Classes, Clinical Pipeline Analysis and Forecast 2013-2020
Maryland Heights, MO, June 26, 2016 --(PR.com)-- According to a market research report published by iHealthcareAnalyst, Inc., Hypertrophic Cardiomyopathy Therapeutics Market – Global HCM Drug Classes, Clinical Pipeline Analysis and Forecast 2013-2020, the global hypertrophic cardiomyopathy therapeutics market growing at a rate of 1.8% CAGR, is estimated to reach USD 1.2 Billion by 2020 due to high incidence chronic cardiovascular diseases.
Browse Hypertrophic Cardiomyopathy Therapeutics Market – Global HCM Drug Classes, Clinical Pipeline Analysis and Forecast 2013-2020 at http://www.ihealthcareanalyst.com/report/hypertrophic-cardiomyopathy-therapeutics-market/
Hypertrophic cardiomyopathy (HCM) is a heterogeneous cardiac disease with a diverse clinical presentation and course. It is also a common inherited heart disease with serious adverse outcomes, including heart failure, arrhythmias, and sudden cardiac death. Medications include beta blockers, calcium channel blockers, and, rarely, diltiazem, amiodarone, and disopyramide. The hypertrophic cardiomyopathy therapeutics market report estimates the market size (Revenue USD million - 2013 to 2020) for key market segments based on the drug classes (antiarrhythmic agents, anticoagulants, beta adrenergic blocking agents, and calcium channel blockers) and clinical pipeline analysis of phase 1, 2 and 3 drugs, and forecasts growth trends (CAGR% - 2015 to 2020). It also provides the detailed market landscape and profiles of major competitors in the global market including company overview, financial snapshot, major products and services offered, and recent trends in strategic management.
The global hypertrophic cardiomyopathy therapeutics market is segmented as:
1. Drug Class
1.1. Antiarrhythmic Agents
1.2. Anticoagulants
1.3. Beta Adrenergic Blocking Agents
1.4. Calcium Channel Blockers
2. Pipeline Analysis
2.1. Clinical Trials (Phase 1, 2 and 3)
3. Geography (Region, Country)
3.1. North America (U.S., Canada)
3.2. Latin America (Brazil, Mexico, Rest of LA)
3.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
3.4. Asia Pacific (Japan, China, India, Rest of APAC)
3.5. Rest of the World
4. Company Profiles
4.1. Astra Zeneca plc
4.2. Concordia Healthcare Corp.
4.3. Gilead Sciences, Inc.
4.4. Merck & Co., Inc.
4.5. Mylan N.V.
4.6. Novartis AG
4.7. Pfizer, Inc.
4.8. Sanofi S.A.
4.9. Teva Pharmaceutical Industries Ltd.
About Us
iHealthcareAnalyst, Inc. is a global health care market research and consulting company providing market analysis, and competitive intelligence services to global clients. The Company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.
iHealthcareAnalyst, Inc. provides industry participants and stakeholders with strategically analyzed, unbiased view of market dynamics and business opportunities within its coverage areas.
Contact Us
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Email: sales@ihealthcareranalyst.com
Website: http://www.ihealthcareanalyst.com
Browse Hypertrophic Cardiomyopathy Therapeutics Market – Global HCM Drug Classes, Clinical Pipeline Analysis and Forecast 2013-2020 at http://www.ihealthcareanalyst.com/report/hypertrophic-cardiomyopathy-therapeutics-market/
Hypertrophic cardiomyopathy (HCM) is a heterogeneous cardiac disease with a diverse clinical presentation and course. It is also a common inherited heart disease with serious adverse outcomes, including heart failure, arrhythmias, and sudden cardiac death. Medications include beta blockers, calcium channel blockers, and, rarely, diltiazem, amiodarone, and disopyramide. The hypertrophic cardiomyopathy therapeutics market report estimates the market size (Revenue USD million - 2013 to 2020) for key market segments based on the drug classes (antiarrhythmic agents, anticoagulants, beta adrenergic blocking agents, and calcium channel blockers) and clinical pipeline analysis of phase 1, 2 and 3 drugs, and forecasts growth trends (CAGR% - 2015 to 2020). It also provides the detailed market landscape and profiles of major competitors in the global market including company overview, financial snapshot, major products and services offered, and recent trends in strategic management.
The global hypertrophic cardiomyopathy therapeutics market is segmented as:
1. Drug Class
1.1. Antiarrhythmic Agents
1.2. Anticoagulants
1.3. Beta Adrenergic Blocking Agents
1.4. Calcium Channel Blockers
2. Pipeline Analysis
2.1. Clinical Trials (Phase 1, 2 and 3)
3. Geography (Region, Country)
3.1. North America (U.S., Canada)
3.2. Latin America (Brazil, Mexico, Rest of LA)
3.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
3.4. Asia Pacific (Japan, China, India, Rest of APAC)
3.5. Rest of the World
4. Company Profiles
4.1. Astra Zeneca plc
4.2. Concordia Healthcare Corp.
4.3. Gilead Sciences, Inc.
4.4. Merck & Co., Inc.
4.5. Mylan N.V.
4.6. Novartis AG
4.7. Pfizer, Inc.
4.8. Sanofi S.A.
4.9. Teva Pharmaceutical Industries Ltd.
About Us
iHealthcareAnalyst, Inc. is a global health care market research and consulting company providing market analysis, and competitive intelligence services to global clients. The Company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.
iHealthcareAnalyst, Inc. provides industry participants and stakeholders with strategically analyzed, unbiased view of market dynamics and business opportunities within its coverage areas.
Contact Us
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Email: sales@ihealthcareranalyst.com
Website: http://www.ihealthcareanalyst.com
Contact
iHealthcareAnalyst, Inc.
Ana Aitawa
(314) 736-9294
http://www.ihealthcareanalyst.com/
Ana Aitawa
(314) 736-9294
http://www.ihealthcareanalyst.com/
Contact
Categories